Literature DB >> 19086089

In vivo microdialysis in awake, freely moving rats demonstrates HIV-1 Tat-induced alterations in dopamine transmission.

Mark J Ferris1, Danielle Frederick-Duus, Jim Fadel, Charles F Mactutus, Rosemarie M Booze.   

Abstract

Individuals infected with human immunodeficiency virus (HIV) may develop neuropsychological impairment, and a modest percentage may progress to HIV-associated dementia (HAD). Research using human and nonhuman, in vitro and in vivo models, demonstrates that subcortical dopamine (DA) systems may be particularly vulnerable to HIV-induced neurodegeneration. The goal of the current investigation is to provide an understanding of the extent to which the HIV-1 protein Tat induces alterations in striatal DA transmission using in vivo brain microdialysis in awake, freely moving rats. The current study was designed to investigate Tat-induced neuronal dysfunction between 24-h and 48-h post-Tat administration, and demonstrates a reduction in evoked DA for the Tat-treated group relative to vehicle-treated group at 24 and 48 h. The Tat-induced reduction of DA overflow by 24 h suggests dysfunction of nerve terminals, and a compromised DA system in Tat-treated animals. Furthermore, the current study provides direct support for HIV-associated decline of DA function at a systemic level, helping to characterize the functional outcome of the relatively large amount of research on the molecular and behavioral levels of HIV-induced neurotoxicity. This initial study may provide additional characteristics of Tat-induced neuronal dysfunction to inform research on therapeutic intervention, and it provides a springboard for future in vivo research currently needed in the field. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19086089      PMCID: PMC3704183          DOI: 10.1002/syn.20594

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  18 in total

Review 1.  Involvement of dopamine in the progression of AIDS Dementia Complex.

Authors:  E Koutsilieri; S Sopper; C Scheller; V ter Meulen; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  2002-03       Impact factor: 3.575

2.  Oxidative damage induced by the injection of HIV-1 Tat protein in the rat striatum.

Authors:  M Y Aksenov; U Hasselrot; A K Bansal; G Wu; A Nath; C Anderson; C F Mactutus; R M Booze
Journal:  Neurosci Lett       Date:  2001-06-01       Impact factor: 3.046

Review 3.  Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia.

Authors:  A Nath; C Anderson; M Jones; W Maragos; R Booze; C Mactutus; J Bell; K F Hauser; M Mattson
Journal:  J Psychopharmacol       Date:  2000       Impact factor: 4.153

4.  Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist.

Authors:  J R Glowa; L V Panlilio; D E Brenneman; I Gozes; M Fridkin; J M Hill
Journal:  Brain Res       Date:  1992-01-20       Impact factor: 3.252

5.  Temporal relationships between HIV-1 Tat-induced neuronal degeneration, OX-42 immunoreactivity, reactive astrocytosis, and protein oxidation in the rat striatum.

Authors:  Michael Y Aksenov; Ulla Hasselrot; Guanghan Wu; Avindra Nath; Carol Anderson; Charles F Mactutus; Rosemarie M Booze
Journal:  Brain Res       Date:  2003-10-10       Impact factor: 3.252

6.  Neurotoxicity of HIV-1 proteins gp120 and Tat in the rat striatum.

Authors:  A K Bansal; C F Mactutus; A Nath; W Maragos; K F Hauser; R M Booze
Journal:  Brain Res       Date:  2000-10-06       Impact factor: 3.252

7.  HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat.

Authors:  Wayne A Cass; Michael E Harned; Laura E Peters; Avindra Nath; William F Maragos
Journal:  Brain Res       Date:  2003-09-12       Impact factor: 3.252

8.  Neonatal intrahippocampal injection of the HIV-1 proteins gp120 and Tat: differential effects on behavior and the relationship to stereological hippocampal measures.

Authors:  Sylvia Fitting; Rosemarie M Booze; Charles F Mactutus
Journal:  Brain Res       Date:  2008-07-17       Impact factor: 3.252

9.  The in vivo microdialysis recovery of dopamine is altered independently of basal level by 6-hydroxydopamine lesions to the nucleus accumbens.

Authors:  L H Parsons; A D Smith; J B Justice
Journal:  J Neurosci Methods       Date:  1991-12       Impact factor: 2.390

10.  Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine.

Authors:  J Turchan; C Anderson; K F Hauser; Q Sun; J Zhang; Y Liu; P M Wise; I Kruman; W Maragos; M P Mattson; R Booze; A Nath
Journal:  BMC Neurosci       Date:  2001-03-02       Impact factor: 3.288

View more
  27 in total

1.  Role of Macrophage Dopamine Receptors in Mediating Cytokine Production: Implications for Neuroinflammation in the Context of HIV-Associated Neurocognitive Disorders.

Authors:  R A Nolan; R Muir; K Runner; E K Haddad; P J Gaskill
Journal:  J Neuroimmune Pharmacol       Date:  2018-12-05       Impact factor: 4.147

2.  Preferential sensitivity of human dopaminergic neurons to gp120-induced oxidative damage.

Authors:  Shuxian Hu; Wen S Sheng; James R Lokensgard; Phillip K Peterson; R Bryan Rock
Journal:  J Neurovirol       Date:  2009-09       Impact factor: 2.643

3.  Evidence for developmental dopaminergic alterations in the human immunodeficiency virus-1 transgenic rat.

Authors:  Katy M Webb; Michael Y Aksenov; Charles F Mactutus; Rosemarie M Booze
Journal:  J Neurovirol       Date:  2010-03       Impact factor: 2.643

4.  Selective monoaminergic and histaminergic circuit dysregulation following long-term HIV-1 protein exposure.

Authors:  Adam R Denton; Srimal A Samaranayake; Kristin N Kirchner; Robert F Roscoe; Shane N Berger; Steven B Harrod; Charles F Mactutus; Parastoo Hashemi; Rosemarie M Booze
Journal:  J Neurovirol       Date:  2019-05-17       Impact factor: 2.643

5.  HIV-1 TAT protein enhances sensitization to methamphetamine by affecting dopaminergic function.

Authors:  James P Kesby; Julia A Najera; Benedetto Romoli; Yiding Fang; Liana Basova; Amanda Birmingham; Maria Cecilia G Marcondes; Davide Dulcis; Svetlana Semenova
Journal:  Brain Behav Immun       Date:  2017-05-08       Impact factor: 7.217

Review 6.  Drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia.

Authors:  Vishnudutt Purohit; Rao Rapaka; David Shurtleff
Journal:  Mol Neurobiol       Date:  2011-07-01       Impact factor: 5.590

7.  D1/NMDA receptors and concurrent methamphetamine+ HIV-1 Tat neurotoxicity.

Authors:  Michael Y Aksenov; M V Aksenova; C F Mactutus; Rosemarie M Booze
Journal:  J Neuroimmune Pharmacol       Date:  2012-05-03       Impact factor: 4.147

8.  Methamphetamine-induced behavioral sensitization is enhanced in the HIV-1 transgenic rat.

Authors:  Xiangqian Liu; Linda Chang; Michael Vigorito; Marley Kass; He Li; Sulie L Chang
Journal:  J Neuroimmune Pharmacol       Date:  2009-05-15       Impact factor: 4.147

9.  HIV-1 Tat protein-induced rapid and reversible decrease in [3H]dopamine uptake: dissociation of [3H]dopamine uptake and [3H]2beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane (WIN 35,428) binding in rat striatal synaptosomes.

Authors:  Jun Zhu; Charles F Mactutus; David R Wallace; Rosemarie M Booze
Journal:  J Pharmacol Exp Ther       Date:  2009-03-26       Impact factor: 4.030

10.  The human immunodeficiency virus-1-associated protein, Tat1-86, impairs dopamine transporters and interacts with cocaine to reduce nerve terminal function: a no-net-flux microdialysis study.

Authors:  M J Ferris; D Frederick-Duus; J Fadel; C F Mactutus; R M Booze
Journal:  Neuroscience       Date:  2009-01-20       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.